King's College London

Research portal

Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4′-Phosphopantothenoyl- l -cysteine Synthetase (CoaB) Activity

Research output: Contribution to journalArticlepeer-review

Joanna C. Evans, Dinakaran Murugesan, John M. Post, Vitor Mendes, Zhe Wang, Navid Nahiyaan, Sasha L. Lynch, Stephen Thompson, Simon R. Green, Peter C. Ray, Jeannine Hess, Christina Spry, Anthony G. Coyne, Chris Abell, Helena I.M. Boshoff, Paul G. Wyatt, Kyu Y. Rhee, Tom L. Blundell, Clifton E. Barry, Valerie Mizrahi

Original languageEnglish
Pages (from-to)1666-1679
Number of pages14
JournalACS Infectious Diseases
Volume7
Issue number6
DOIs
Published11 Jun 2021

Bibliographical note

Funding Information: This work was supported by HIT-TB (OPP1024021) and SHORTEN-TB (OPP1158806) grants from the TB Drug Accelerator program of the Bill and Melinda Gates Foundation (to C. E. Barry III, K. Y. Rhee, and V. Mizrahi), the South African Medical Research Council, the National Research Foundation of South Africa, and an International Research Scholar’s grant from the HHMI (to V. Mizrahi) and, in part, by the Intramural Research Program of NIAID (H. I. M. Boshoff and C. E. Barry III). J. Hess was financially supported by the Swiss National Science Foundation (SNSF Early PostDoc Mobility Fellowship, P2ZHP2_164947) and the Marie Curie Research Grants Scheme, EU H2020 Framework Programme (H2020-MSCA-IF-2017, ID: 789607). C. Spry was funded in part by a NHMRC Overseas Biomedical Fellowship (1016357) and in part by the Bill and Melinda Gates Foundation HIT-TB (OPP1024021). T. L. Blundell is funded by the Wellcome Trust (Wellcome Trust Investigator Award 200814_Z_16_Z: RG83114). CoaBC screening was funded by a MRC-CinC (Grant No. MC_PC_14099). We thank Alex Cookson, Kirsty Cookson, Emma Gutcher, and Desiree Zeller for assistance with compound logistics. Publisher Copyright: ©

King's Authors

Abstract

Coenzyme A (CoA) is a ubiquitous cofactor present in all living cells and estimated to be required for up to 9% of intracellular enzymatic reactions. Mycobacterium tuberculosis (Mtb) relies on its own ability to biosynthesize CoA to meet the needs of the myriad enzymatic reactions that depend on this cofactor for activity. As such, the pathway to CoA biosynthesis is recognized as a potential source of novel tuberculosis drug targets. In prior work, we genetically validated CoaBC as a bactericidal drug target in Mtb in vitro and in vivo. Here, we describe the identification of compound 1f, a small molecule inhibitor of the 4′-phosphopantothenoyl-l-cysteine synthetase (PPCS; CoaB) domain of the bifunctional Mtb CoaBC, and show that this compound displays on-target activity in Mtb. Compound 1f was found to inhibit CoaBC uncompetitively with respect to 4′-phosphopantothenate, the substrate for the CoaB-catalyzed reaction. Furthermore, metabolomic profiling of wild-type Mtb H37Rv following exposure to compound 1f produced a signature consistent with perturbations in pantothenate and CoA biosynthesis. As the first report of a direct small molecule inhibitor of Mtb CoaBC displaying target-selective whole-cell activity, this study confirms the druggability of CoaBC and chemically validates this target.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454